CAR-T Meeting 2020 | CRISPR/Cas9 edited T-cells in MM and sarcoma
Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses the feasibility and safety of multiplex genetic engineering of autologous T-cells expressing NY-ESO-1 T-cell receptors (TCR) and CRISP/Cas9 gene-edited to eliminate endogenous TCR and PD-1 (NYCE T-cells) in advanced multiple myeloma (MM) and sarcoma. Dr Levine reveals that safety and feasibility of manufacturing were demonstrated and there was indication of some therapeutic effect in the sarcoma patients. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
Get great new content delivered to your inboxSign up